| Project/Area Number |
23790601
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
WAKE HIDENORI 岡山大学, 医歯(薬)学総合研究科, 助教 (60570520)
|
|---|
| Research Collaborator |
NISHIBORI Masahiro 岡山大学, 医歯薬学総合研究科, 教授 (50135943)
LIU Keyue 岡山大学, 医歯薬学総合研究科, 助教 (40432637)
TAKAHASHI Hideo 近畿大学, 医学部, 教授 (60335627)
MORI Shuji 就実大学, 薬学部, 教授 (50220009)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 薬物治療学 / 抗体医薬 / 抗腫瘍薬 / HMGB1 |
|---|
| Research Abstract |
The osmotic pump continuous dosing of anti-HMGB1 antibody for 7 days significantly reduced tumor growth in mouse tumor graft model, whereas the same dose of anti-KLH antibody (control) had no effect on tumor growth. In the group treated with anti-HMGB1 antibody, the number of CD31-positive blood vessel in tumor tissue was significantly decreased in comparison with the number by treatment with anti-KLH antibody. However, the administration of anti-HMGB1 antibody had no effect on tumor growth in tumor graft model using immune-deficient mice. These data suggested that anti-HMGB1 antibody reduced tumor growth not directly but through immune response.
|
